Key result
Nisoldipine coat-core reduced clinic and ambulatory blood pressure to a similar degree as ACE inhibitors, beta-blockers, and other calcium antagonists in patients with hypertension.
Why the study?
Does nisoldipine coat-core reduce blood pressure in patients with hypertension?
Does nisoldipine coat-core reduce blood pressure in patients with hypertension?
Nisoldipine coat-core is an effective and well-tolerated once-daily therapy for the management of hypertension, with efficacy comparable to other major antihypertensive classes.
Answers are grounded in this paper and cite their sources.
Supports nisoldipine coat-core as a once-daily option; leaves open need for prospective outcome trials.
Nisoldipine coat-core (CC), a 1,4-dihydropyridine calcium antagonist, is indicated for the treatment of hypertension and may be used alone or in combination with other antihypertensive agents. The CC technology allows for extended delivery of the drug and once-daily dosing. Nisoldipine CC tablets are absorbed across the entire gastrointestinal tract, including the colon. Eighty percent of the total dose is in the slow-release outer coat, while the core has immediate-release characteristics suitable for absorption in the distal gastrointestinal tract. Numerous double-blind, randomized studies of this agent have been done in patients with hypertension. The use of nisoldipine CC reduced both clinic and ambulatory blood pressure to a similar degree when compared with angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and the calcium antagonists amlodipine and felodipine. The drug has also been studied in hypertensive African Americans and demonstrated equivalent efficacy to amlodipine. Tolerability of the drug is good, with the most common side effect of edema at a rate similar to other dihydropyridine calcium antagonists. Thus, results of more than a decade of clinical trial data support the use of nisoldipine CC as once-daily therapy for the treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
William B. White (2007) conducted a review in hypertension. Nisoldipine coat-core vs. ACE inhibitors, beta-blockers, amlodipine, and felodipine was evaluated on clinic and ambulatory blood pressure. Nisoldipine coat-core reduced clinic and ambulatory blood pressure to a similar degree as ACE inhibitors, beta-blockers, and other calcium antagonists in patients with hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: